Biohacking Kompakt

Supplement

Melatonin

Hormone · Sleep hormone

12 min read 11 sources, checked November 13, 2026

In the BK-Score: Supported, with caveats – human evidence 7 out of 10, safety data 7 out of 10. There are several studies in humans, but they are small, short or inconsistent.

Melatonin shortens the time it takes to fall asleep – most clearly where the internal clock runs against the desired sleep time: in delayed sleep phase syndrome by 38.8 minutes, and for jet lag across at least five time zones, 9 of 10 randomized trials showed an effect. In ordinary insomnia, by contrast, the effect is small: the largest meta-analysis puts it at around seven minutes.

What melatonin is

Melatonin is a hormone made by the body, released in darkness, that controls the day-night rhythm. In foods it occurs only in trace amounts, for example in cherries and pistachios. As a food supplement, market doses according to the BfR range from 0.1 to 3 mg; online, products of up to 10 mg are available.

In the BK-Score it gets 7 out of 10 points for human evidence and 9 out of 10 for mechanism. Long-term data are largely lacking. According to the BfR, the daily amounts of products listed in Germany are 0.1 to 3 mg and thus not above the 0.5 to 5 mg mostly used in studies.

How it works

Melatonin shifts and stabilizes the circadian rhythm, that is, the internal clock. This chain of action is quantified in humans. It explains why the substance works most strongly where the internal clock runs against the desired sleep time – with time zone changes and with a shifted sleep phase.

As a sleep aid in ordinary insomnia, by contrast, the effect is small. The authors of the largest meta-analysis explicitly describe it as smaller than that of established sleeping pills.

What is well supported

  • Jet lag across five or more time zones: the most robust use case. In the Cochrane review by Herxheimer 2002, melatonin reduced jet lag in 9 of 10 randomized trials, taken close to the target bedtime between 10 p.m. and midnight. The participants were airline passengers, flight crew and military personnel. There are no pooled effect sizes; the data date from 2002.
  • In delayed sleep phase syndrome, the effect is large. Buscemi 2005 puts the reduction in time to fall asleep there at 38.8 minutes (−50.3 to −27.3) – compared with 7.2 minutes in insomnia. This breakdown is based on 2 studies.
  • Three endpoints, all significant, across 19 randomized trials. Ferracioli-Oda 2013 analyzed 1,683 adults and children with primary sleep disorders: time to fall asleep 7.06 minutes shorter (4.37 to 9.75; p less than 0.001), total sleep time +8.25 minutes (1.74 to 14.75; p = 0.013), sleep quality SMD 0.22 (0.12 to 0.32; p less than 0.001). With continued use, the effect did not wane. The authors explicitly describe it as smaller than that of established sleeping pills.
  • The dose question has been answered. In the Cochrane review, 0.5 to 5 mg worked similarly; at 5 mg, participants fell asleep faster and slept better than at 0.5 mg, and above 5 mg there was no additional benefit. A 2 mg slow-release form was relatively ineffective. The mechanism behind it – the shift of the circadian rhythm – is quantified in humans and gets 9 out of 10 points in the BK-Score.

What the studies show

Seven minutes: the figure from the largest meta-analysis

Ferracioli-Oda 2013 analyzed 19 randomized placebo-controlled trials with 1,683 adults and children with primary sleep disorders. Time to fall asleep shortened by 7.06 minutes (95 % interval 4.37 to 9.75; p less than 0.001), total sleep time rose by 8.25 minutes (1.74 to 14.75; p = 0.013), and sleep quality by SMD 0.22 (0.12 to 0.32; p less than 0.001). Higher doses and longer use had stronger effects, and the effect did not wane with continued use.

Broken down: where the effect is large and where it is not

For short-term use of up to four weeks in primary sleep disorders, Buscemi 2005 found an overall 11.7 minutes shorter time to fall asleep (−18.2 to −5.2). The breakdown is the real finding: in delayed sleep phase syndrome it was −38.8 minutes (−50.3 to −27.3; 2 studies), in insomnia, by contrast, only −7.2 minutes (−12.0 to −2.4; 12 studies). The authors concluded that melatonin is not effective in the short term for most primary sleep disorders.

Jet lag: the most robust use case

A Cochrane review by Herxheimer 2002 analyzed 10 randomized trials in airline passengers, flight crew and military personnel. In 9 of 10 trials, melatonin taken close to the target bedtime, that is, between 10 p.m. and midnight, reduced jet lag across at least five time zones. On dose: 0.5 to 5 mg worked similarly; at 5 mg, participants fell asleep faster and slept better than at 0.5 mg, and above 5 mg there was no additional benefit. A 2 mg slow-release form was relatively ineffective. There are no pooled effect sizes; the data date from 2002.

Where the data stop

  • A clinically relevant effect in ordinary insomnia. Seven minutes less time to fall asleep is statistically significant, but the authors themselves describe the effect as smaller than that of established sleeping pills. Buscemi 2005 considers melatonin not effective in the short term for most primary sleep disorders.
  • Benefit of higher doses for jet lag. Above 5 mg, the Cochrane review found no additional effect. According to the BfR, products sold online go up to 10 mg.
  • Benefit on flights across few time zones. The jet lag finding applies from at least five time zones crossed. Below that, these studies provide no evidence.
  • Safety of use over years. Controlled long-term trials are missing. A non-peer-reviewed congress finding from 2025 with more frequent heart failure stands against an analysis showing no association; both are observational data.

Status, approval and legal

In the EU, melatonin is also approved as a medicine, among other things as a 2 mg slow-release tablet for the short-term treatment of primary insomnia from age 55. In Germany, it is in principle prescription-only as a medicine. Since May 23, 2026, there has been an exception: under the 24th amendment to the German Prescription Drugs Ordinance (AMVV), melatonin for oral use against jet lag in adults is available without a prescription, limited to 3 mg per tablet or capsule, a maximum daily dose of 3 mg and packs of up to 30 mg. This describes the legal framework, not a recommendation to take it.

Alongside this, melatonin is sold freely as a food supplement. Legally, food supplements are foods, and there is no statutory maximum amount for melatonin in them. The often-quoted limit of 1 mg is not a ceiling but a floor for advertising claims: under Regulation (EU) No 432/2012, the EU claim “contributes to the reduction of time taken to fall asleep” is only permitted with at least 1 mg per serving, the jet lag claim from 0.5 mg. The German Federal Institute for Risk Assessment assessed melatonin in its statement 42/2024 of September 17, 2024. Key message: a robust health-based maximum level cannot be derived. The BfR advises against use in children and adolescents, during pregnancy and breastfeeding, and in liver and kidney dysfunction, autoimmune diseases and epilepsy.

Safety

As reported side effects, the BfR lists drowsiness, headache, prolonged reaction time, drop in blood pressure, nightmares and morning grogginess. The prolonged reaction time matters in everyday life, for example in road traffic. In the BK-Score, safety gets 7 out of 10 points, partly because long-term data are largely lacking. This text is for information and does not replace medical advice.

Long-term use and the heart: a signal, not proof

At the American Heart Association congress in November 2025, a research group presented an analysis of international patient records from the TriNetX network: 130,828 adults with insomnia, 65,414 of them with at least one year of melatonin in their records. Over five years, new heart failure was diagnosed in 4.6 percent of the melatonin group and in 2.7 percent of the matched group. This is an observation, not proof of cause, and according to our research it had not appeared as a peer-reviewed paper by November 2026. The authors name the weaknesses themselves: melatonin bought over the counter in countries such as the US is usually not in the records, and data on the severity of the sleep disorder or on mental illness are missing. A counter-check in Open Heart 2026 using the US population survey NHANES (1999 to 2018) found no significant association with cardiovascular disease or heart failure. It, too, establishes neither harm nor safety: people who take melatonin often sleep worse and are more often depressed than others, and that is exactly what distorts such comparisons.

Children and gummies in the US

In the US, melatonin is sold freely as a dietary supplement, often as gummies. The annual number of reports to US poison control centers of melatonin ingestions in children and adolescents up to 19 years rose by 530 percent from 2012 to 2021, with 260,435 cases in total. 84.4 percent had no symptoms, five children needed mechanical ventilation and two infants died. Labelling is another issue: a test of 25 melatonin gummies sold in the US found 74 to 347 percent of the stated amount, and one product contained no melatonin at all but CBD instead. In Germany, the BfR advises children and adolescents against use.

BK-Score Supported, with caveats

Human evidence7
Mechanism9
Safety data7
Hype gap6
Track record of use9

The circadian chain of action is quantified in humans, and there are meta-analyses on time to fall asleep and on jet lag. Long-term data are largely lacking. According to the BfR, the daily amounts of products listed in Germany range from 0.1 to 3 mg and are thus not above the 0.5 to 5 mg mostly used in studies; online, products with up to 10 mg are also offered.

The score rates the state of knowledge, not the substance. A high safety-data value means well studied – not harmless. A high track-record value means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about melatonin

How does melatonin work?

Melatonin is the body's own signal for darkness and shifts and stabilizes the internal clock. This chain of action is quantified in humans. It explains why the substance works most strongly where the internal clock runs against the desired sleep time, that is, with jet lag and with a shifted sleep phase.

How much faster do you fall asleep with melatonin?

On average, about seven minutes. The largest meta-analysis, with 19 randomized trials and 1,683 participants, found a 7.06 minutes shorter time to fall asleep and 8.25 minutes more total sleep. Both values are statistically significant. The authors, however, explicitly describe the effect as smaller than that of established sleeping pills.

Does melatonin help with jet lag?

This is where the data are best. A Cochrane review of ten randomized trials in airline passengers, flight crew and military personnel found a reduction in jet lag in nine of ten trials when melatonin was taken close to the target bedtime between 10 p.m. and midnight. The finding applies from at least five time zones crossed.

Does a higher dose do more?

Not above five milligrams. The Cochrane review on jet lag found similar efficacy between 0.5 and 5 milligrams, with five milligrams leading to faster sleep onset than 0.5 milligrams. Above five milligrams, there was no additional benefit. According to the German Federal Institute for Risk Assessment, products of up to ten milligrams are sold online.

Is melatonin allowed in Germany?

In Germany, melatonin is sold as a food supplement, with market doses between 0.1 and 3 milligrams. There is no statutory maximum amount; 1 milligram is only the minimum amount for the authorized advertising claim on time to fall asleep. In 2024, the German Federal Institute for Risk Assessment concluded that no robust health-based maximum level can be derived, and it advises children and adolescents as well as pregnant and breastfeeding women against use, among others. As a medicine, melatonin is in principle prescription-only, for example the 2 mg slow-release form for people aged 55 and over with primary insomnia. Since May 23, 2026, there has been an exception: for jet lag in adults, melatonin is available without a prescription in limited strength and pack size.

What side effects does melatonin have?

Reported effects include drowsiness, headache, prolonged reaction time, drop in blood pressure, nightmares and morning grogginess. The prolonged reaction time in particular matters in everyday life. The German Federal Institute for Risk Assessment advises against use in liver and kidney dysfunction, autoimmune diseases and epilepsy. This information does not replace medical advice.

Is melatonin bad for the heart?

That has not been shown. A finding from patient records presented at the American Heart Association congress in 2025 found heart failure more often over five years in adults with insomnia who had at least one year of melatonin in their records, 4.6 versus 2.7 percent. This is an observation, not proof of cause, and it has not yet appeared as a peer-reviewed paper. An analysis of the US population survey NHANES found no association. Controlled long-term data are missing. This information does not replace medical advice.

The podcast episode (in German)

Episode 55

Melatonin: the darkness hormone fact-checked

The podcast by Paul Höser (Episode 55) · with Paul & Paula. The world's best-selling sleep aid, used correctly: a chronobiotic instead of a sleeping pill, the less-is-more dose (Wurtman/MIT: 0.3–1 mg), honestly quantified meta-analyses, jet lag (supported by Cochrane), shift work, the night-owl protocol with an early mini-dose, its second identity as a mitochondrial antioxidant, and red light between physics and marketing. Information only, no dosage or usage recommendation.

Listen on Spotify

Episode page with summary and sources

Related

Similar topics

Questions and comparisons

Sources

Open in the database – with search, filters and comparison (German app)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-11-13.